GLP-1 receptor agonists (GLP-1s) are evolving quickly, not just in terms of clinical evidence, but in how Healthcare Professionals (HCPs) and Patients interpret that evidence based on real life.

With the approval of the first oral GLP-1, the category enters another phase of scale and accessibility. For Medical Communication Agencies the question is not whether GLP-1s matter. It is whether you can track how their meaning is changing for your clients with such a dynamic landscape for HCPs and Patients.

Why the oral GLP-1 approval matters strategically

An oral GLP-1 reduces practical and psychological barriers for Patients, particularly in primary care. This may influence HCP discussions, Patient expectations, and payer assessments, but trends in perception often emerge before they appear in prescribing data.

Why narrative measurement is now a strategy issue

For CCOs and CSOs in Agencies, the lesson from GLP-1s is that evidence alone does not drive adoption. Understanding, interpretation and perception is key.

Traditional insight methods tell you what HCPs and Patients say when prompted. They do not tell you how meaning is forming in real-life discussion, nor how quickly that meaning is changing as new evidence and access models appear.

This is why HCP analytics and AI in Pharma Marketing now sit at the centre of strategic decision making.

Using Message Resonance to track narrative drift

The Message Resonance Score™ quantifies how closely brand, clinical and medical narratives align with real world HCP and Patient understanding.

In fast moving categories like GLP-1s, this allows strategy leaders to see:

• Where evidence is landing with HCPs

• Where patient expectations are diverging from clinical guidance

• Where access models are reshaping trust and confidence

• Where self learning by Patients is influencing opinion

• Where messaging is reinforcing understanding or unintentionally creating friction

This allows strategy teams to monitor emerging trends and avoid blind spots while the category evolves.

What this means for strategy leaders

GLP-1s highlight how fast narratives can change in healthcare. The approval of an oral GLP-1 may accelerate this process.

For Chief Client Officers and Chief Strategy Officers, the advantage no longer comes from being first to say something, but from being first to understand evolving perceptions.

That is what message resonance measurement makes visible.

Get in touch

If you are planning for GLP-1 strategy in 2026 and want to understand how HCPs and Patients are actually understanding key messaging around your Client’s therapy area, we would be happy to show you how this looks through DrugVoice and the Message Resonance Score™. Get in touch.